Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.

M Rodgers, M Soares, D Epstein, H Yang, D Fox, A Eastwood

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalHealth Technology Assessment
Issue numberSupp 1
Publication statusPublished - May 2011

Cite this